Cipla Limited
Indian Pharmaceutical Exporter Β· Respiratory Specialist Β· $1.1B Total Trade Β· DGFT Verified
Cipla Limited is an Indian pharmaceutical exporter with a total trade value of $1.1B across 98 products in 26 therapeutic categories. Based on 29,033 verified export shipments from Indian Customs (DGFT) records, Cipla Limited is the #1 Indian exporter in 18 products including Fluticasone, Amlodipine, Salbutamol. Top exports include Fluticasone ($133.2M), Amlodipine ($101.8M), Salbutamol ($100.3M).
Cipla Limited β Export Portfolio & Destination Treemap

Who is Cipla Limited? β Company Overview & Market Position
Cipla Limited, established in 1935 by Khwaja Abdul Hamied, is a leading Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the development, manufacturing, and distribution of a wide range of pharmaceutical products, including generic and branded generic medicines, vaccines, and active pharmaceutical ingredients (APIs). Cipla's therapeutic portfolio spans areas such as respiratory, cardiovascular, oncology, and infectious diseases.
As of March 2024, Cipla employed approximately 27,764 individuals. The company's equity shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE), where it is a constituent of the BSE SENSEX and the CNX Nifty indices. Additionally, Cipla's Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.